DEA

Ji Paraná, Brazil
Ji Paraná, Brazil
SEARCH FILTERS
Time filter
Source Type

News Article | May 25, 2017
Site: globenewswire.com

NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are expected in July 2017. Patient disqualification and subsequesnt subject recruitment issues  extended the completion date for the study. The study, which began in March 2017, is a pivotal, open-label, randomized, single-dose, three-way, crossover study to evaluate the relative bioavailability and bioequivalence of the modified formulation of SequestOx™ to the original formulation of SequestOx™ and to a comparator product under fed conditions. The reformulated product is expected to have a shorter Tmax than the original SequestOx™ formulation under fed conditions. SequestOx™ is Elite’s investigational immediate-release oxycodone with sequestered naltrexone abuse-deterrent opioid product for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. About Elite’s Abuse Deterrent Technology Elite’s proprietary abuse deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence.  When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases as intended providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist is designed to release and so block the effects of active opioid agonist. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to the same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.  Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management. About Elite Pharmaceuticals, Inc. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse deterrent opioid products as well as niche generic products.  Elite specializes in oral sustained and controlled release drug products which have high barriers to entry.  Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International. Elite currently has eight commercial products being sold, additional approved products pending manufacturing site transfer and the NDA for SequestOx™, for which it received the CRL from the FDA.  Elite’s lead pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, Elite’s ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of SequestOx™ by the FDA, the steps Elite may take as a result of the CRL, and the actions the FDA require of Elite in order to obtain approval of the NDA. These forward-looking statements are not guarantees of future action or performance. These risks and other factors, including, without limitation, Elite’s ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


News Article | May 23, 2017
Site: motherboard.vice.com

Government malware can be seriously powerful tech. Not only do some agencies take advantage of so-called zero day exploits to remotely gain access to a target's device, but the breadth of data malware can obtain from a target device is so rich that it can infringe the privacy of people not suspected of a crime at all—emails, texts, and online messages typically involve more than one person. Regardless, the Drug Enforcement Administration did not carry out a Privacy Impact Assessment—a process which is typically designed to understand and minimize the privacy risks with a particular system or technology—when it bought and ultimately used malware from Italian surveillance company Hacking Team. Privacy experts say the news is consistent with the DEA's repeated failure to complete such assessments around the agency's surveillance operations. In a Freedom of Information request, Motherboard asked the DEA for all Privacy Impact Assessments (PIAs) the DEA has conducted in relation to the Hacking Team's malware, known as Remote Control System (RCS). Motherboard also requested other related files, such as all Privacy Threshold Analysis (PTA) documents and Initial Privacy Assessments (IPAs). However, the DEA did not have any. "As a result of our query, we are unable to locate any records responsive to your request," the response reads. A DEA spokesperson confirmed that the agency did not complete a PIA. Once deployed on a target's iOS, Android or desktop device, RCS is capable of capturing web browsing histories, keystrokes, Skype conversations, and much more. A 2015 Motherboard investigation found that the DEA had bought RCS, and a subsequent Freedom of Information request filed by Motherboard found that the DEA had also been invoiced for access to Hacking Team's selection of zero-day exploits. Many parts of the Department of Justice conduct and publish PIAs, such as the Bureau of Alcohol Tobacco, Firearms and Explosives, and the US Marshals Service. The DEA has some too, including for its system for logging pharmacies who order controlled substances, but it also decides not to complete others for different technologies and programs. Jeramie D. Scott from the Electronic Privacy Information Center (EPIC) pointed to an April letter the organization sent to Congress urging a committee to scrutinize the DEA's compliance with PIAs. In that letter, EPIC highlights that the DEA did not conduct a PIA for its use of the controversial Hemisphere program, in which agents can access AT&T call records without a warrant. EPIC also found through a Freedom of Information Act lawsuit that the DEA had not completed a PIA for the agency's license plate reader database. According to the DEA spokesperson, the agency did not carry out a PIA for RCS because the agency does not produce them for commercial software products. "The lack of privacy assessments for commercial products like the RCS spyware demonstrates that we need stronger oversight, accountability, and transparency requirements," Scott told Motherboard in an email. "The DEA engages in surveillance programs that raise serious privacy and civil liberties issues and the lack of transparency surrounding these programs and the technology the agency uses is troubling and undermines public confidence. All surveillance technology and programs should be subject to a privacy and civil liberties assessment," Scott added. Ultimately, the DEA cancelled its contract with Hacking Team, and, as it turns out, did not use the malware all that much. According to a letter the DEA sent to US Senator Chuck Grassley, the agency deployed RCS on 17 foreign-based drug traffickers and money launderers.


MIAMI, May 23, 2017 (GLOBE NEWSWIRE) -- Former prosecutor and DEA agent Jarrett Wolf today announced the creation of Wolf Global, an international advisory and consulting firm focused on helping lawyers, bankers, senior executives, senior diplomats and ultra high net worth individuals and their family offices navigate legal, commercial, political and reputational crises and risks. Wolf Global combines the experience of professionals who have previously litigated and tried cases to verdict; led government priority investigations; prevented international incidents; responded to investigations, arrests and prosecutions; advised embassies on consular emergencies; and advised ultra high net worth individuals on matters affecting their lives, wealth and reputations. “We’ve been able to make a difference for clients by responding quickly and discreetly to serious and often sensitive matters,” said Jarrett Wolf, president of Wolf Global. “I describe it as being called into bad situations and being asked to change the outcome. What’s equally important to note, however, is that based on our experience, we’ve often been able to proactively help clients avoid those bad situations in the first place.” The firm is organized into four complementary practice areas: Wolf, who began his career as a prosecutor, litigating and trying cases, was later recruited by the DEA as a Special Agent and spent the next several years investigating international drug trafficking and money laundering organizations. “When you go from being a prosecutor to being an agent, instinctively, you start putting together cases in real time,” said Wolf.  “You think in terms of proof. You know how the rules of evidence and the jury instructions will be applied. You anticipate how a judge or a jury will react.” In 2006, Wolf left the DEA to join Ferrell Law as a litigation partner and developed a crisis management practice, responding to and handling cases throughout the U.S. at the request of an embassy. In 2009, he created Wolf, P.A. to continue working with embassies as well as private clients, and Group One Consulting to work with law firms, banks and corporate clients taking a new look at money laundering, corruption and fraud. Wolf Global combines the non-legal crisis management and international advisory of Wolf, P.A. with the investigations, intelligence and risk mitigation of Group One. Wolf Global, Inc. is an international advisory firm focused on delivering results in sensitive, discreet and complex matters affecting the lives, wealth and reputations of its clientele. Certain investigations are conducted by Wolf Global Consulting, Inc., a licensed private investigative agency, licensed by the New York State Department of State, license number 11000194412; and licensed by the State of Florida, license number A1400279. For more information, please visit wolfglobal.com or call 1-305-377-8006.


MIAMI, May 23, 2017 (GLOBE NEWSWIRE) -- Former prosecutor and DEA agent Jarrett Wolf today announced the creation of Wolf Global, an international advisory and consulting firm focused on helping lawyers, bankers, senior executives, senior diplomats and ultra high net worth individuals and their family offices navigate legal, commercial, political and reputational crises and risks. Wolf Global combines the experience of professionals who have previously litigated and tried cases to verdict; led government priority investigations; prevented international incidents; responded to investigations, arrests and prosecutions; advised embassies on consular emergencies; and advised ultra high net worth individuals on matters affecting their lives, wealth and reputations. “We’ve been able to make a difference for clients by responding quickly and discreetly to serious and often sensitive matters,” said Jarrett Wolf, president of Wolf Global. “I describe it as being called into bad situations and being asked to change the outcome. What’s equally important to note, however, is that based on our experience, we’ve often been able to proactively help clients avoid those bad situations in the first place.” The firm is organized into four complementary practice areas: Wolf, who began his career as a prosecutor, litigating and trying cases, was later recruited by the DEA as a Special Agent and spent the next several years investigating international drug trafficking and money laundering organizations. “When you go from being a prosecutor to being an agent, instinctively, you start putting together cases in real time,” said Wolf.  “You think in terms of proof. You know how the rules of evidence and the jury instructions will be applied. You anticipate how a judge or a jury will react.” In 2006, Wolf left the DEA to join Ferrell Law as a litigation partner and developed a crisis management practice, responding to and handling cases throughout the U.S. at the request of an embassy. In 2009, he created Wolf, P.A. to continue working with embassies as well as private clients, and Group One Consulting to work with law firms, banks and corporate clients taking a new look at money laundering, corruption and fraud. Wolf Global combines the non-legal crisis management and international advisory of Wolf, P.A. with the investigations, intelligence and risk mitigation of Group One. Wolf Global, Inc. is an international advisory firm focused on delivering results in sensitive, discreet and complex matters affecting the lives, wealth and reputations of its clientele. Certain investigations are conducted by Wolf Global Consulting, Inc., a licensed private investigative agency, licensed by the New York State Department of State, license number 11000194412; and licensed by the State of Florida, license number A1400279. For more information, please visit wolfglobal.com or call 1-305-377-8006.


News Article | May 25, 2017
Site: globenewswire.com

NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are expected in July 2017. Patient disqualification and subsequesnt subject recruitment issues  extended the completion date for the study. The study, which began in March 2017, is a pivotal, open-label, randomized, single-dose, three-way, crossover study to evaluate the relative bioavailability and bioequivalence of the modified formulation of SequestOx™ to the original formulation of SequestOx™ and to a comparator product under fed conditions. The reformulated product is expected to have a shorter Tmax than the original SequestOx™ formulation under fed conditions. SequestOx™ is Elite’s investigational immediate-release oxycodone with sequestered naltrexone abuse-deterrent opioid product for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. About Elite’s Abuse Deterrent Technology Elite’s proprietary abuse deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence.  When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases as intended providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist is designed to release and so block the effects of active opioid agonist. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to the same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.  Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management. About Elite Pharmaceuticals, Inc. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse deterrent opioid products as well as niche generic products.  Elite specializes in oral sustained and controlled release drug products which have high barriers to entry.  Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International. Elite currently has eight commercial products being sold, additional approved products pending manufacturing site transfer and the NDA for SequestOx™, for which it received the CRL from the FDA.  Elite’s lead pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, Elite’s ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of SequestOx™ by the FDA, the steps Elite may take as a result of the CRL, and the actions the FDA require of Elite in order to obtain approval of the NDA. These forward-looking statements are not guarantees of future action or performance. These risks and other factors, including, without limitation, Elite’s ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


News Article | May 12, 2017
Site: www.theenergycollective.com

Stock divestment strategies have been widely proposed to undercut financial support for fossil fuels. The German lignite industry, however, cannot be tackled in this way, writes independent energy expert Jeffrey Michel in a highly informative analysis. Lignite stations and mines are owned by regional communities in the west and a Czech consortium in the east. Although some power plants are being phased out against government-arranged subsidies, pulling away from lignite usage altogether is not so simple and may not be a good idea. It would leave unpaid obligations behind for mining landscape reclamation and groundwater management and might lead to political backlash. Dealing with lignite requires local policies and strategies to develop feasible alternatives.  According to the German chapter of 350.org, the capital of Berlin is the only German state to have divested its government pension reserves of €823 million from fossil fuel investments. Similar resolutions adopted last year in North Rhine-Westphalia, Baden-Württemberg and Rhineland-Palatinate have not yet been implemented. However, such intentions could have little effect on domestic lignite policy. Germany’s largest lignite corporation, RWE, is partially owned by regional municipalities. Eastern Germany’s lignite industry is largely in the hands of private investors from the Czech Republic. Both businesses are being reorganized for greater operating efficiency and increased public acceptance. Up to a year ago, western German lignite production was integrated into the cumbersome corporate structure at RWE in Essen. In addition to mining, the company handled generation, transmission, marketing, innovations, and foreign acquisitions. Renewable energies produced only 4.8% of total generated electricity in 2014, less than one-fifth of the German national average. Due to declining revenues at conventional power plants, regular stock dividends were cancelled for the 85 cities, counties, regional utilities (Stadtwerke), and local banks in the communal shareholder association VkA. Greenpeace Cologne has compiled a map of all RWE municipal entities, most of them in North Rhine-Westphalia, with over one million shares. Besides selling its DEA natural gas division, the corporation has discharged 10,000 employees (14% of total staffing) over the last three years to reduce operating costs. By 2018, another 2,000 positions will be eliminated. After RWE disputed the need for splitting the company to emulate its market rivals E.ON (renewables) and Uniper (conventional generation), an inverted strategy was finally resolved. CEO Peter Terium assumed responsibility for the green power subsidiary Innogy originally founded in 2008. The exceptionally successful corporate IPO of October 7, 2016, has provided fresh revenues for lignite mining and power generation. Since the beginning of this year, the listed RWE share price has risen by 30% to nearly €16. Before that time, certain municipal shareholders had considered divesting their holdings to preclude further revenue erosion. The city of Bochum began divesting its 6.6 million RWE shares last year at a unit price below €15, compared with €100 a decade ago. The county of Osnabrück also passed a resolution to sell its 2.1 million shares, but the transaction was then postponed indefinitely. The IPO spinoff has since provided RWE with €680,000 of Innogy dividends. The newly organized RWE now aspires to provide backup power generation capacities for the electrical grid whenever renewable energies prove inadequate. By 2022, all remaining eight nuclear reactors in Germany and 70 additional power plants will have been retired, reducing current generation capacities of 107 gigawatts by more than 30 GW. Keeping the remaining infrastructure supplied with power would cost an estimated €2 billion per year in the estimation of CEO Rolf Martin Schmitz, which “is not much in comparison with €25 billion for green power subsidies”.  The proposed capacity reserves would “prevent the electricity price from going through the roof” whenever power became scarce. RWE can now reduce CO emissions on the path to increased profitability. Lignite extraction at the Garzweiler mine is being continued until 2045, but 400 Mt of the 1.2 billion metric tons at this location will no longer be excavated. The three villages (Holzweiler, Dackweiler & Hauerhof) thereby saved from destruction will present no further corporate risk. Additional generating blocks are also likely to be retired over the next few years. Realizing enhanced revenues with less ecological damage should restrain both popular protests and communal deliberations on divestment. When the Czech consortium EPH/PPF Investments acquired Vattenfall’s lignite operations last September, the stock market became irrelevant to mining and generation. The renamed energy corporation LEAG nevertheless announced a significant reduction of lignite mining on March 13 owing to “the obvious will on the part of federal policy” to pursue Germany’s climate goals “on the back of lignite”. Not only is long-term planning at question, but “even intervention into licensed stockpiles is now acceptable”. As in the case of RWE, however, selective decarbonization is helping to sidestep mining opposition. Electricity generation will likely be continuing at the LEAG Schwarze Pumpe, Boxberg, and Lippendorf power stations for at least another two decades. For the aging 2,720 MW Jänschwalde installation 130 km southeast from Berlin, however, two of the six blocks will now be entering standby operation in 2018 – 19 under a reimbursement agreement with the federal ministry of economic affairs BMWi. Since the adjacent mine can be appropriately downsized, LEAG will no longer be resettling the villages of Atterwasch, Kerkwitz, and Grabko. The area’s 900 inhabitants had already begun a regional energy transformation. In 2014, Atterwasch alone generated more electricity than required by all three communities using animal waste biogas (up to 3.5 MWh/a) and 40 kWp installed solar PV capacity. Farther south in Saxony, the Nochten mine that serves the Boxberg power station will also be confined to existing boundaries. Excavation plans for the endangered communities of Schleife, Rohne, and Mulkwitz have been cancelled, leaving only the resettlement of 200 villagers in the vestigial Mühlrose settlement necessary for extracting an additional 150 Mt of lignite.  The suburb of Proschim at the third Welzow mine, however, faces three more years of corporate indecision over its ultimate fate. The revised mining plans have been unexpected. Some families had already bought land elsewhere after the 2012 Vattenfall license application foresaw resettling 1,700 residents from the four Nochten villages. Since existing homes could not be sold without an indemnification agreement, however, particular property owners may now be saddled with two mortgages. Stanislaw Tillich, premier minister of Saxony, has emphasized a standing agreement with the federal government to place economic development on an alternative basis before cutting back on lignite usage. However, the mining regions have always been susceptible to changes in EU emissions regulations and to overall carbon pricing. The LEAG decision in Lusatia has shown, furthermore, that the lignite corporations have made no forward commitments to maintaining the economic viability of regions they ultimately will be abandoning. LEAG is already saving resettlement costs for all six villages while reducing the extent of post-mining precautionary risks. Despite the low-cost extraction of lignite from opencast mines, its low thermal rating requires vast areas of landscape to be excavated and later ecologically restored using reserved corporate assets. The commitments required of LEAG for this purpose have been the subject of a recent confidential report presented to the parliament of Saxony by the state accounting office. Numerous fossil fuel plant acquisitions by EPH in the UK, Italy, and Eastern Europe have rendered the company’s financial assets opaque. After Greenpeace issued its updated EPH Schwarzbuch (Black Book) at the beginning of the year, the government of Brandenburg conceded that it had no legal means of verifying the use of €1.7 billion transferred by Vattenfall to cover post-mining indemnities. With mining landscapes already disfigured, extensive efforts are required even to inhibit the ongoing deterioration of the natural environment. In recent years, unexpectedly high levels of acidified groundwater have been rising from formerly excavated lignite seams near the Brandenburg River Spree and the Leipzig Pleiße basin. The mining wastewater pervasively contaminates lakes and tributaries  with iron sulfate that is chemically transformed to indelible brown hydroxide (FeS + 7/2 O + H O → Fe2+ + 2SO 2- + 2 H+). The resulting aquatic damage persists for decades until groundwater currents finally attain a state of equilibrium. Bizarrely, combating acidic groundwater can be one of the arguments for the continuation of mining. East German lignite dependency intensified in the 1980’s after the Soviet invasion of Afghanistan had raised import energy prices. The sharp decline of lignite mining after 1990 has now reduced the pumping discharges that could be needed to dilute contaminated lake and river water. Recent iron sulfate leaching at Witznitz, for instance, has acidified the Pleiße watershed to levels as low as pH 2.6. Possibly for hydrological reasons, therefore, MIBRAG has been attempting to resettle the nearby village of Pödelwitz and the adjacent hamlet of Obertitz despite the unfounded need for extra lignite at the Lippendorf power station. RWE has already shown that profits can be increased by focusing generation on periods of high grid demand. Nevertheless, extracting additional quantities of lignite would make more water available, while local sand deposits from ancient riverbeds might also be exploited. The meager financial resources of the six rescued Lusatian communities had largely been dedicated to the expected resettlement of over 3,000 people. Following revised LEAG planning, the governments of Brandenburg and Saxony are now obligated to preserve the very rural villages that their previous energy policies had been dedicated to destroying. Many Eastern German lignite communities are highly indebted after returning millions of euros in tax revenues to Vattenfall in result of corporate losses from nuclear phase-out. Solar and wind farms provide no equivalent income prospects. To begin with, each wind turbine qualifies as a separate tax entity with a €24.500 annual exemption. Homes with rooftop solar panels are literally just cottage industries. The regional decline of mining employment has provoked unforeseen political consequences. LEAG’s sister corporation MIBRAG decided in April 2015 to cancel the intended construction of a 660 MW lignite power plant at its Profen mine near Leipzig. The requirement for that project had long been questioned. Renewable energy generation in the state of Saxony-Anhalt already fills half of local electricity demand. The growing forward-looking risks of coal power generation have been recently verified by a Bloomberg analysis. The abandoned Profen generation project had promised 4,000 highly qualified construction jobs. Thereafter, 150 permanent plant employees would have been required, with 3 Mt annual lignite demand also securing a sixth of total MIBRAG mining production. An additional 2 Mt/a of Profen lignite would have been delivered to the Buschhaus power plant near the Volkswagen factory in Lower Saxony. In implementing national climate strategies, however, the German government instead provided MIBRAG with an estimated €200 million of ratepayer funds in 2016 to relegate Buschhaus to standby operation, with retirement four years thereafter. Together with the two blocks at Jänschwalde and an additional five in the Rhineland, Germany will be saving around 12 Mt of CO emissions annually at a total compensation cost of €1.61 billion. Reducing lignite requirements has had significant political repercussions on MIBRAG territory. Following cancellation of the Profen plant, local membership in the right-wing Alliance for Germany (AfD) soared. Founded in 2013, the party already captured 24.3% of the seats in Saxony-Anhalt’s parliamentary elections just three years later. The AfD rejects renewable energy feed-in tariffs and national climate protection policies. Following the additional cancellation of lignite deliveries to Buschhaus, employment at Profen will now be reduced by over 320 miners – nearly one-fifth of regular MIBRAG personnel – by 2018. Further disquieting news was recently published in the 2015 MIBRAG corporate report for the 5 Mt of Profen lignite delivered annually to the 900 MW power station at Schkopau, erected in 1995 as the centerpiece of Dow Chemical operations and local railway (16 2/3 Hz) generation. Due to sinking profitability, the “economic viability of the Schkopau power plant” has become “particularly vulnerable”. The current lignite supply contract ends in 2021 with corresponding “implications for the further development of the open pit mine”. The possible resulting sale of MIBRAG to LEAG by its current owner EPH could reduce the cost of lignite supplied from the second United Schleenhain mine to the Lippendorf power station. Regional employment and third-party contracts, however, would likely be diminished. The AfD may make one claim with confidence: The abandonment of lignite never delivers immediate economic alternatives. When the 352 MW MIBRAG Buschhaus plant in Lower Saxony ceased regular operation on October 1, 2016, mining and generation were eliminated as the principal source of regional public revenues. A decade ago, business taxes of up to €10 million annually had been collected from the Buschhaus site by cities in Helmstedt County. The German federal government has now provided a solitary grant of €900,000 for implementing a “structured development process” to produce “new economic prospects for the region”. However, local communities formerly unprepared for this abrupt transition are now compelled to implement its fulfillment. The corresponding opportunity for low-carbon development can compensate the retirement of the 1985 Buschhaus power plant, for which CO certificates (about 2.2 Mt/a) have not been retired, but only auctioned off under the EU emissions trading scheme ETS. The rescued villages of Lusatia are currently adrift in unused fields of lignite. Entrepreneurial investment might be attracted to these regions by providing specialized financing and insurance, strategic community services, and dedicated programs of education and training organized by the state employment office. The need for fiscal rigor had often been neglected during the era of lignite prosperity. Today, however, the legal interest rate of 6% on retroactive Vattenfall tax refunds has become incompatible with applicable taxation provisions of the civil code HGB. Particular communities may soon be proposing corrective legislative initiatives. Regional chambers of commerce routinely evaluate the international strategies of corporations on local territory. Dow Chemical is already equipped to integrate the Energiewende into its expanded production plans at Schkopau. The U.S. parent corporation recently raised renewable electricity contracts to 750 MW by 2025 for its Texas operations. Much of the European chemical industry is concentrated in traditional coal and lignite regions. Plants with high emissions are located along prospective CO pipeline routes. An international fossil fuel divestment campaign might only injure or eliminate these sites. To continue their operation, existing equipment could instead be gradually converted to renewable energies supplemented by CCS for carbon-based processes.


WHIPPANY, N.J.--(BUSINESS WIRE)--Halo Pharma announces the formation of its Pediatric Center of Excellence in support of the development and manufacture of dosage forms tailored for pediatric indications. Halo Pharma has been working closely with pharmaceutical companies to apply its extensive expertise in formulation sciences and its fully integrated manufacturing capabilities across a broad range of scales and dosage forms to overcome the challenges in developing pediatric dosage forms (PDFs) of already approved adult dosage forms. Halo Pharma is proud to be the manufacturer of choice for many of today’s largest pharma companies having been selected to reformulate multiple products across a variety of dosage forms. Companies have come to rely on Halo Pharma as a trusted partner to provide specialized contract development and manufacturing services that meet the regulatory requirements of the U.S., Canada, and Europe, where Halo Pharma is already manufacturing PDFs for commercial sale through its sponsors. Pharmaceutical companies are often asked by the U.S. Food and Drug Administration to conduct clinical trials for pediatric indications of adult dosage forms. The advantages of developing PDFs include the potential for extended patent protection and to obtain expanded indications in pediatric populations. In support of its Pediatric Center of Excellence, Halo Pharma has developed the infrastructure, process trains and equipment needed for efficient, cost-effective, and rapid production of small- to medium-scale cGMP clinical drug products that are used in pediatric clinical studies. Companies that partner with Halo Pharma benefit from close collaboration with our formulation scientists who provide the technical expertise needed to modify adult dosage forms for pediatric use. This may include reformulation to enable a lower strength or making changes to the adult dosage form to improve patient compliance by making the medication easier to take and/or taste better. Halo Pharma has partnered with several pharmaceutical companies already to develop commercially viable PDFs that have received both U.S. and international regulatory approvals. Halo Pharma currently has multiple clinical and commercial PDF programs underway. In nearly all cases, developing a PDF from an adult dosage form requires additional product development work. In many cases, it is necessary to provide the PDF in various strengths matched to different pediatric age/weight brackets. Halo Pharma has the capabilities to manufacture batches of PDFs that typically range in scale from 5 Kg to 1000 Kg, with many requiring multiple processing steps. “Our formulation development and clinical manufacturing capabilities can support a variety of oral solid and liquid dosage forms suitable for pediatric applications, such as granules produced using fluid bed technology and mini-tablets that can be packaged into stick packs, powder in bottles for reconstitution, and our liquid products, which are typically oral solutions and suspensions that can also be time release-based,” says Lee Karras, CEO of Halo Pharma. “We offer our customers over 40 years of commercial drug manufacturing experience and a proven track record of approvals with regulatory agencies around the world," Mr. Karras adds. Halo Pharma can help your company develop, test, and bring to market pediatric dosage forms of your drug products quickly and cost effectively. To learn more about Halo Pharma's new Pediatric Center of Excellence visit www.Halopharma.com/pediatric. Halo Pharmaceutical is a rapidly growing contract development and manufacturing organization (CDMO) that provides scientific and development expertise as well as a wide spectrum of manufacturing services from its locations in Whippany, New Jersey USA and Montreal, Quebec Canada to its international client base. Halo Pharma offers fully integrated capabilities in a variety of dosage forms including tablets, capsules, powders, liquids, creams, sterile and non-sterile ointments and suppositories. The company is registered to work with any of these dosages in the CI-CV DEA designations. Halo Pharmaceutical’s capabilities in the areas of tech transfer, process and product development, production, scale-up/validation and analytical method development allow us to partner with clients from development through commercialization or at any point along the way. For more information please contact services@Halopharma.com.


For additional information or to register for CPhI North America and InformEx 2017, please visit: www.cphinorthamerica.com or www.informex.com. Registration to either event offers full access to both exhibition floors. While more than 630 leading solution providers will populate the exhibition floor, the following are some of the highlights: Aavis Pharmaceuticals Inc. (booth 3210) - Has established a brand new facility and will serve as a CDMO offering end-to-end pharmaceutical development and manufacturing solutions. Capabilities as an integrated service provider and experience with a range of technologies enables ability to serve both innovator and generic companies worldwide. ACIC (booth 2431) - A full-service pharmaceutical company providing API, finished formulations and pharmaceutical machinery. The ACIC service relationship is a very flexible one structuring custom services to meet client needs. Alphora Research Inc. (booth 2138) - Provides API technology development and scale-up services for complex small molecules, including niche APIs, high potency and cytotoxic compounds. Our services cover IND enabling development, phase II & III, and commercial manufacturing of niche APIs. Amcor Flexibles (booth 3105) - Focused on improving sterile fluid delivery with barrier embedded primary containers which remove steps at critical points-of-care, maintain product integrity, and improve product stability. Anguil Environmental Systems (booth 940) - Air pollution control technologies and techniques applied to the pharmaceutical and chemical processing industries for regulatory compliance. Aptar Pharma (booth 3102) – Offering a breakthrough Ophthalmic Squeeze Dispenser, the first and only FDA-reviewed multi-dose delivery system to handle preservative-free eye treatment formulations with metal-free pathways. B&W Tek (booth 3025) - The i-Raman Pro ST is a new portable Raman system that can see through opaque packaging to identify the material inside. Bausch Advanced Technology Group (booth 3114) - Triple Container Filling & Stoppering Machine Type 535 is a flexible modular processing machine featuring three different filling systems: rotary piston pump, peristaltic pump and time pressure on one platform to offer the most flexibility for customers. Baxter BioPharma Solutions (booth 2454) - Baxter's BioPharma Solutions facility in Bloomington, Indiana, was recently recognized as the "Best Contract Manufacturing Organization" at the 2017 Annual Vaccine Industry Excellence (ViE) Awards. Benzo Chem Industries PVT. LTD. (booth 2241) - Manufacturers of pharmaceutical and agro intermediates with four ISO compliant plants. An additional GMP plant will begin operations in August 2017. Bormioli Rocco (booth 3112) - A wide range of Type I Glass, Amber and Flint, produced in a pharma approved environment, following the highest quality standards. Bosch Packaging Technology (booth 3201) - The Solidlab 2 is a multifunctional system capable of granulating, drying and coating with flexible batch sizes from 0.25 to 12 kilograms. BUCHI Corporation (booth 1252) - Introducing the first freeze dryer with unlimited capacity for continuous freeze drying. The Lyovapor L-300 offers two alternately working condensers that automatically clean while freezing down to -105°C. Capricorn Life Sciences (booth 3001) – Out-licensing food supplements, medical devices and pharmaceutical OTC's under brand names or private label. ChemicalInfo (booth 2240) - Directory of World Chemical Producers (DWCP) connects buyers and sellers of chemicals and pharmaceuticals with global producer details including contact and product information. Chemo Dynamics, Inc. (booth 938) - U.S. based CRO/CMO with cGMP facility providing pharmaceutical and biopharmaceutical contract research, custom synthesis, analytical service and small quantity manufacturing. CordenPharma (booth 2160) - Offers development & manufacturing expertise across specialized technology platforms from regulated raw materials through intermediates, APIs, drug product manufacturing & packaging. CurTec  (booth 2231) - Presenting Pharma Grade Packo, screw top jars that have been tested according to European and U.S. Pharmacopoeia and are suitable as primary packaging for pharmaceuticals. DATWYLER (booth 3204) - Offering a unique range of products and services including the most advanced elastomer formulations, coatings, aluminum seals, and processing technologies. EAS Consulting Group, LLC (booth 2551) - Provider of FDA regulatory consulting services, with more than 50 years of experience. Capabilities include performing cGMP audits and mock FDA inspections, quality system implementation and remediation, product development and regulatory strategies, to submissions, filings, registrations, assistance with imports and acting as an U.S. Agent. EMBOCAPS by Suheung (booth 2733) - Introducing a premium empty capsule product line - EMBOCAPS VG ALPHA.  No gelling agents, pH independent disintegration profile, and superior machinability. Erawat Pharma Limited (booth 3126) - An ultra-modern facility brings you hard capsules in easy fitting, sticky free, liquid filling, metallic , preservative and SLS free varieties driven by best standards of quality and consumer satisfaction. FabriChem, Inc. (booth 2121) - D-Galactose from plant origin, L-Tyrosine and L-Leucine from corn protein (vegetable origin) for use in bio pharmaceuticals & cell culture. 1, 2, 6 Hexane triol for moisturizing agent in creams, Guanidine hydrochloride for biopharmaceuticals, Dipicolinic Acid & Alpha Picolinic Acid. FAR Chemical, Inc. (booth 1234) - Manufacturer of fine and specialty chemicals sold to a variety of industries and applications including: pharmaceutical reagents and intermediates, advanced polymers, organometallics, silane & bromine chemistries, and structural composites. Flamma (booth 2344) - Flamma will open its cGMP workshop at Flamma Honkai (Dalian, China) in June providing customers a trusted partner to integrate projects from Italy to China. Also, project managers have been added in Italy and China in order to better serve customers, new capabilities have been added and land has been acquired for company growth and expansion. Fresenius Kabi Product Partnering (booth 2938) - The contract manufacturing platform of Fresenius Kabi offers manufacturing expertise of more than 20 facilities worldwide. A full range of services for both fill and finish of solutions are provided along with emulsions in ampoules, vials, bottles, IV-bags, and pre-filled syringes. Frontida BioPharm, Inc. (booth 2865) - Proprietary AdaptDoseTM encapsulation platform and DuraGran® coated granule technology provides speed, precision, flexibility and cost-savings in the product development through commercialization process. Large U.S., high-capacity facility, with expertise in controlled release granules, fluid bed operations, solvent processing, DEA controlled substances, HPAPI and nanoparticle milling. Fuji Chemical Industries Co., Ltd. (booth 2354) - Sales and marketing of unique specialty excipients, and the contract manufacturing and development of solid dispersion processing with closed spray driers. GBR - Global Business Reports (booth 3261) - Launching the U.S. Pharmaceuticals 2017 book which provides in-depth global analysis and up-to-date insights into all aspects of the oil and gas, pharmaceuticals, chemicals, energy, aerospace and mining industries. Grifols  (booth 3037) - Premixed solutions ready-to-use in PP bag deliver a fixed dose in 50 mL to 1 L ensuring accurate delivery of the drug to the patient. Groupe PARIMA (booth 2807)   - A CDMO specialized in the development and manufacturing of liquids, suspensions, semi-solids and sprays. GSK Contract Manufacturing (booth 3111) - Offering a fully integrated supply chain solution to the pharma/biopharm industry with FDA & EMA approved, multi-product facilities along with providing multiple services for Consumer and OTC markets. Haemopharm Healthcare S.r.l. (booth 3124) - Showing the first needle-free technology that not only enables the use of the syringe without the needle, but also provides a hermetic closure, minimizing contaminations and increasing safety. This patented needle-free technology has been applied to both vials (NIV®) and bags (NIP®). Halo Pharma (booth 3132) - Delivering pediatric products from clinical through commercialization (Microtablets, Stickpacks, Granules for Suspensions, Oral Solutions/Suspensions). Recognized as a Pediatric Center of Excellence. Heraeus (booth 2441) - Specializes in the production of generic pharmaceutical ingredients and is the worldwide leading supplier of Platinum hAPIs. International Process Plants (IPP) (booth 1245) - Used equipment offers the highest value rating possible by offering equipment for < 50% off new with delivery times in days instead of months. I.R.A. Istituto Ricerche Applicate (booth 2257) - Linear and cross linked hyaluronic acid for aesthetic and orthopedic fillers. Kingchem Life Science LLC (booth 1324) – Offers complex chemistry products, processes and capabilities including: Boronic acids, heterocyclic chemistry, halogenations, fluorinated compounds including trifluoromethyl and difluoroderivatives, nucleophilic fluorination, cyogenic chemistry, isocyanates, large Scale HF and KF chemistry. Laurus Labs Limited (booth 1100) - Laurus Generics has combined innovation with efficiency by developing cost effective processes to develop an in-house range of APIs and related intermediates. Laurus Synthesis strives to be recognized as the definitive example of "East Meets West" drug development by combining unparalleled front-end process chemistry expertise in both the U.S. and India with world-class back-end API manufacturing resources. LF of America Corp. (booth 3106) - Contract manufacturing, packaging manufacturing and contract filling of liquid sterile solutions in unit-dose delivery systems. LGC Standards (booth 3241) - LGC Standards is an ISO Guide 34, ISO/IEC 17025 accredited manufacturer offering more than 4,000 pharmaceutical reference standards including: impurities, APIs, excipients and primary standards LGM Pharma (booth 2501) - Provides comprehensive cGMP API sourcing solutions backed by complete technical and regulatory capabilities to a diverse array of U.S. pharmaceutical companies. Macco Organiques, s.r.o. (booth 2554) - cGMP (GMP, Q7 certified), well recognized production and supplier of inorganic and organic mineral salts for the pharmaceutical and biopharmaceutical industry, infant formulas producers, food and beverage manufacturers. ManageArtworks (booth 3235) - Packaging artwork management software that helps life science companies manage the processes, text matter, design and other components of a packaging artwork via an electronic workflow. As a CFR Part 11 compliant system, it offers transparency with effortless tracking, audit trails, alerts and dashboards. Novasep (booth 1456) - Announced that its new €11M antibody-drug conjugate bioconjugation facility is now operational to support our pharmaceutical customers in developing the latest innovative treatments against cancer. Ompi - Stevanato Group (booth 3207) - Developed a new fully passive and fully customizable, integrated needlestick protection - the Ompi EZ-fill® Integrated Safety System (ISS). It provides automatic shield retraction in an elegant and highly customizable way. PCI Synthesis (booth 2128) - Pharmaceutical development CMO based in Newburyport, MA is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. Polpharma Pharmaceutical Works (booth 2250) - A cGMP-compliant and a FDA-approved European producer of API, providing a wide-range of services including FDF out-licensing and supply and contract manufacturing services. PolyCine GmbH (booth 3223) - Global leader for the packaging of IV solution bags providing: standard films and tubes, peelable films for multi-chamber bags, special films for lipids, gas barrier films, overwrap films, filling & transfer tubes, special modified granules & compounds and hot stamping foil. Polycrystalline (booth 2253) - With the mission of "Crystallization by Design," providing services for the research and development of highly potent API and controlled substances/narcotics. Polycrystalline shares protocols, methods, and raw data customizing activities to meet specifics clients' goals, timeframes and budget. PolyPeptide Group (booth 924) - A world leading GMP peptide (CDMO) with six facilities worldwide in Belgium, France, India, Sweden, San Diego and Torrance. Potasse et Produits Chimiques (booth 1034) - Extensive technical experience for bromination, hydrobromination and related technologies. Brominated compounds are widely used in specialty chemicals, in pharmaceuticals, agrochemicals, polymer additives, and cosmetics products as intermediates. PQE US, Inc. (booth 3130) - Global consulting firm specializing in the life sciences industry. Provides global support in: data integrity assurance, computer system validation, qualification and engineering, quality assurance and compliance and regulatory affairs. Pressure Chemical Co. (booth 1444) - Providing pilot, scale-up, and custom contract manufacturing services in a flexible facility with highly experienced project leaders and operations; enabling clients to: gather process information, reduce startup capital, and bridge the gap beyond current capabilities. Q Laboratories, Inc. (booth 3134) - Provides microbiology, analytical chemistry and research & development laboratory services and helps companies worldwide meet the level of excellence they demand to produce safe, high-quality products. Qosina Corporation (booth 3236) - Purchasing components from Qosina save you both time and money by eliminating tool costs and providing immediate delivery of in-stock solutions. Qualicaps (booth 2913) - Quali-V® capsules are plant-based alternative to gelatin capsules designed to meet the demanding requirements of the pharmaceutical industry. R-Pharm Germany GmbH (booth 3135) - CDMO providing manufacturing, packaging, serialization, formulation, scale-up, product-launch, analytics and stability, as well as high potency API manufacturing. REACHLaw Ltd. (booth 1052) - Offers chemical regulatory compliance helping clients gain market access for their chemical products. Services include: REACH Only Representation, REACH Registrations, REACH Authorisation, REACH Out-Tasking, Advocacy Services, Global Notifications and Consultancy Services. Regis Technologies Inc. (booth 1124) – Utilizing analytical and synthesis expertise, offers a complete structure elucidation package to support IND and NDA filings. Reliance Label Solutions (booth 1013) - GHS, BS 5609 and IMDG certified compliance labeling solutions via the www.theghsstore.com. Rohner Inc. (booth 1151) - This Swiss custom manufacturer will be unveiling their new portfolio of Multi-Customer Products that utilize their core competencies. Roquette (booth 2829) - Features new product offerings that are low endotoxin, multi-compendial grade materials for cell culture and biologic drug formulations. Sabin Metal Corporation (booth 1254) - Provides worldwide customers with logistical support, precious metal financial services, pre-reclaim kilning and safe, accurate and responsible processing, sampling and refining of PM-bearing catalysts. Senn Chemicals AG (booth 2142) - Operates cGMP and ISO certified facilities specializing in the production of peptides and amino acid derivatives. Contract manufacturer that provides the pharmaceutical and cosmetic industry with customized products and individual solutions starting from small scale for R&D, process development, scale-up to commercial production. SK Life Science Inc. (booth 2051) - A global life sciences company known for its presence in custom chemical development, advanced intermediates and active pharmaceutical ingredient (API) manufacturing including a continuous flow process for low temperature and high pressure reaction. Symbiotica Specialty Ingredients SDN. BHD. (booth 2365) - Malaysian manufacturer of steroids with ICH Q7A GMP certification. The site was successfully inspected by the U.S. FDA in 2014 and have filed 8 U.S. DMFs: hydrocortisone valerate, clobetasol propionate, mometasone furoate, betamethasone dipropionate, betamethasone valerate, dexamethasone sodium phosphate, exemestane, halobetasol propionate. Takasago International Corporation (booth 1200) - Possesses Nobel Prize winning technology including commercial experience in continuous flow manufacturing on tonne scale. Facility is FDA Inspected. TCG Lifesciences (booth 943) - Since 2001 TCG Lifesciences, a leading CDMO, offers discovery chemistry and biology services, process development, scale-up, and cGMP manufacturing with >700 highly trained scientists and 3 facilities in Kolkata and Hyderabad. Tergus Pharma (booth 2737) - A full-service topical pharmaceutical research, development, testing and manufacturing company that has been an industry leader for more than 20 years with a state-of-the-art facility in Durham, North Carolina. "Think Topical. Think Tergus." Toronto Research Chemicals (booth 2430) - Extensive product base of 90,000+ bio-chemicals manufactured and used by more than 15,000 researchers and companies in more than 100 countries worldwide. UNIPHARMA, LLC (booth 3043) - Features innovative blow-fill-seal packaging solutions: unit dose, fill seal, liquid stickpacks and conventional filling. Both contract manufacturing and private label products in a FDA compliant, GMP facility. VanDeMark Chemical Inc. (booth 1212) - Provides phosgene chemistry for many markets including pharma, agro, personal care, coatings, sealants & adhesives, plastics, polymers, etc. Ward/Kraft, Inc. (booth 941) - Kansas-based, print manufacturer specializing in the production of forms, labels and plastic products offering GHS and BS5609 section 2 & 3 certified labels. Wego Chemical Group (booth 1027) - Triflic acid and Triflic anhydride have long been used for a number of important reactions in pharmaceutical chemistry and asymmetric synthesis. Now they are more economical than ever thanks to world class production and global distribution. WeylChem (booth 1034) - Offers custom tolling and manufacturing services, as well as advanced intermediate products for the specialty and pharmaceutical markets. To see a full list of exhibitors and the floor plan, click here. Participate in the Epicenter of Pharmaceutical and Specialty Chemical Innovation CPhI North America and InformEx 2017 attendees have access to the sold-out expo floor, featuring more than 630 companies across the complete pharma supply chain, as well as show floor programming, networking events, and much more. With its unique blend of unprecedented global influence and the infrastructure to advance relationships between buyers and sellers, CPhI North America and InformEx will provide a marketplace of solutions and ideas unlike any other. Not yet registered for CPhI North America or InformEx? Free registration ends May 15 - register now! CPhI drives growth and innovation at every step of the global pharmaceutical supply chain, from drug discovery to finished dosage. Through exhibitions, conferences, and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities, and expand the global market. CPhI hosts events across Europe, Asia, and now North America, and co-locates with ICSE for contract services; P-MEC for machinery, equipment, and technology; InnoPack for pharmaceutical packaging; and BioPh for biopharma. CPhI provides an online buyer and supplier directory at CPhI-Online.com. UBM Americas, a part of UBM plc, delivers events and marketing services in the fashion technology, licensing, advanced manufacturing, automotive and powersports, healthcare, veterinary, and pharmaceutical industries, among others. Through a range of aligned interactive environments, both physical and digital, UBM Americas increases business effectiveness for customers and audiences through meaningful experiences, knowledge, and connections. The division also includes UBM Brazil's market-leading events in construction, cargo transportation, logistics and international trade, and agricultural production; and UBM Mexico's construction, advanced manufacturing, and hospitality services shows. For more information, visit: www.ubmamericas.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/leading-pharmaceutical-and-specialty-chemical-solution-providers-highlight-innovation-at-cphi-north-america-and-informex-2017-300454063.html

Loading DEA collaborators
Loading DEA collaborators